SCHEMBL4861157

SCHEMBL4861157

CCCCC(=O)c1ccc(OC)c(OC)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 3/20 0.67
WNT3A P56704 3/20 0.67
PDE4D Q08499 5/20 0.66
PDE4A P27815 4/20 0.66
PDE4B Q07343 4/20 0.66
PDE4C Q08493 4/20 0.66
THRA P10827 1/20 0.61
THRB P10828 1/20 0.61
HDAC3 O15379 1/20 0.58
HDAC2 Q92769 1/20 0.58
TSHR P16473 2/20 0.58
MAPT P10636 1/20 0.58
CYP1A2 P05177 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2C9 P11712 1/20 0.58
CYP2C19 P33261 1/20 0.58
CA12 O43570 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
CA4 P22748 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29670763 1.00 CTNNB1 (0.67) CTNNB1WNT3APDE4DPDE4APDE4B
SCHEMBL9375696 0.95 CTNNB1 (0.65) CTNNB1WNT3APDE4DPDE4APDE4B
SCHEMBL9588048 0.94 THRA (0.66) CTNNB1WNT3APDE4DPDE4APDE4B
SCHEMBL31556192 0.91 CTNNB1 (0.73) CTNNB1WNT3APDE4DPDE4APDE4B
SCHEMBL31556194 0.90 CTNNB1 (0.71) CTNNB1WNT3APDE4DPDE4APDE4B
SCHEMBL30313764 0.90 CTNNB1 (0.71) CTNNB1WNT3APDE4DPDE4APDE4B
SCHEMBL6600362 0.90 CTNNB1 (0.71) CTNNB1WNT3APDE4DPDE4APDE4B
SCHEMBL25262527 0.88 PDE4D (0.58) CTNNB1WNT3APDE4DPDE4APDE4B
SCHEMBL10455919 0.88 CTNNB1 (0.83) CTNNB1WNT3APDE4BTSHRMAPT
SCHEMBL26141260 0.87 KDM4E (0.60) PDE4DPDE4APDE4BPDE4CCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114737228-B Circuit board electrotinning brightener and application thereof 深圳市板明科技股份有限公司 2022-08-26 CN claimed
CN-114737228-A Circuit board electrotinning brightener and application thereof 深圳市板明科技股份有限公司 2022-07-12 CN claimed
CN-114737228-B Circuit board electrotinning brightener and application thereof 深圳市板明科技股份有限公司 2022-08-26 CN disclosed
CN-114737228-B Circuit board electrotinning brightener and application thereof 深圳市板明科技股份有限公司 2022-08-26 CN disclosed
CN-114737228-A Circuit board electrotinning brightener and application thereof 深圳市板明科技股份有限公司 2022-07-12 CN disclosed
CN-114737228-A Circuit board electrotinning brightener and application thereof 深圳市板明科技股份有限公司 2022-07-12 CN disclosed
US-9902710-B2 Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) EXONHIT THERAPEUTICS, SA (FR) 2018-02-27 US disclosed
US-9902710-B2 Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) EXONHIT THERAPEUTICS, SA (FR) 2018-02-27 US disclosed
US-9902710-B2 Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) EXONHIT THERAPEUTICS, SA (FR) 2018-02-27 US disclosed
US-20170158606-A1 FLUORINE-CONTAINING COMPOUND, SUBSTRATE FOR PATTERN FORMATION, PHOTODEGRADABLE COUPLING AGENT, PATTERN FORMATION METHOD, AND COMPOUND KANAGAWA UNIVERSITY (JP) 2017-06-08 US disclosed
US-9606437-B2 Fluorine-containing compound, substrate for pattern formation, photodegradable coupling agent, pattern formation method, and compound KANAGAWA UNIVERSITY (JP) 2017-03-28 US disclosed
US-6844359-B2 Substituted imides CELGENE CORPORATION (US) 2005-01-18 US disclosed
US-20020143027-A1 Novel substituted imides MULLER GEORGE W (US) 2002-10-03 US disclosed
US-6429221-B1 INHIBITORS OF TUMOR NECROSIS FACTOR; USED TO TREAT CACHEXIA, ENDOTOXIC SHOCK, AND RETROVIRUS REPLICATION CELGENE CORPORATION 2002-08-06 US disclosed
EP-0800514-A1 SUBSTITUTED IMIDES AS TNF INHIBITORS CELGENE CORPORATION (US) 1997-10-15 EP disclosed
WO-1996020926-A9 SUBSTITUTED IMIDES AS TNF INHIBITORS 1996-09-26 WO disclosed
WO-1996020926-A1 SUBSTITUTED IMIDES AS TNF INHIBITORS CELGENE CORPORATION (US) 1996-07-11 WO disclosed
US-4757084-A Pharmaceuticals MERCK & CO., INC. (US) 1988-07-12 US disclosed
EP-0217204-A1 Trans-2-(3,4,5-trimethoxyphenyl)-5-(5,6-dimethoxy-3-pyridyl)-tetrahydrothiophene, a PAF-antagonist MERCK & CO. INC. (US) 1987-04-08 EP disclosed
EP-0154887-A1 New 2,5-diaryl tetrahydrothiophenes and analogs thereof as paf-antagonists MERCK & CO. INC. (US) 1985-09-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143027-A1 Novel substituted imides TNF, MIF, TNFRSF1A CTNNB1 3154/4885WNT3A 4135/4885PDE4D 4166/4885
US-20170158606-A1 FLUORINE-CONTAINING COMPOUND, SUBSTRATE FOR PATTERN FORMATION, PHOTODEGRADABLE COUPLING AGENT, PATTERN FORMATION METHOD, AND COMPOUND AFF1, AFF2, AFF4 CTNNB1 2620/4885WNT3A 2057/4885PDE4D 4160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.